Kestra Investment Management LLC Acquires 3,499 Shares of Johnson & Johnson (NYSE:JNJ)

Kestra Investment Management LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 16.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,422 shares of the company’s stock after purchasing an additional 3,499 shares during the quarter. Kestra Investment Management LLC’s holdings in Johnson & Johnson were worth $3,532,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Atria Wealth Solutions Inc. boosted its position in Johnson & Johnson by 1.7% during the fourth quarter. Atria Wealth Solutions Inc. now owns 162,782 shares of the company’s stock valued at $23,542,000 after purchasing an additional 2,784 shares during the last quarter. Kornitzer Capital Management Inc. KS raised its stake in shares of Johnson & Johnson by 1.5% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 349,105 shares of the company’s stock worth $50,488,000 after purchasing an additional 5,251 shares in the last quarter. Mraz Amerine & Associates Inc. boosted its holdings in shares of Johnson & Johnson by 38.9% in the 4th quarter. Mraz Amerine & Associates Inc. now owns 24,118 shares of the company’s stock valued at $3,488,000 after buying an additional 6,760 shares during the last quarter. Venturi Wealth Management LLC grew its stake in shares of Johnson & Johnson by 61.7% in the fourth quarter. Venturi Wealth Management LLC now owns 19,662 shares of the company’s stock valued at $2,843,000 after buying an additional 7,502 shares in the last quarter. Finally, Citizens & Northern Corp increased its holdings in Johnson & Johnson by 14.7% during the fourth quarter. Citizens & Northern Corp now owns 2,555 shares of the company’s stock worth $370,000 after buying an additional 327 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $159.62 on Friday. The firm has a 50-day moving average price of $148.61 and a two-hundred day moving average price of $155.89. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The company has a market capitalization of $384.29 billion, a P/E ratio of 24.00, a P/E/G ratio of 2.49 and a beta of 0.52. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.29 earnings per share. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Insider Buying and Selling

In other news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

JNJ has been the subject of a number of analyst reports. Raymond James decreased their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Bank of America reduced their price target on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Citigroup dropped their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Guggenheim lifted their target price on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Finally, Wolfe Research began coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $170.67.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.